
PTC Therapeutics (PTCT) Stock Forecast & Price Target
PTC Therapeutics (PTCT) Analyst Ratings
Bulls say
PTC Therapeutics is poised for growth due to its diversified therapeutic portfolio, successful commercial products, and promising pipeline in rare disorders, indicating a long-term opportunity. The company's strong leadership with high female representation and focus on developing different modalities make it well-positioned for future success. While risks remain, including uncertainty in launch sustainability, a downside scenario may present a potential entry point as PTC continues to solidify its balance sheet and pursue profitable growth.
Bears say
PTC Therapeutics is facing sustainability issues related to manufacturing, data transparency, and clinical trial conduct, and drug pricing, which may affect its long-term growth prospects. Additionally, its significant exposure to international markets could bring unique challenges. While the potential for Sephience and early signals from PTC518 could bring short-term success, a slowdown in uptake and developmental/regulatory delays could result in a downside scenario for the company. Furthermore, PTC Therapeutics has not fully monetized its double-digit royalties on Evrysdi, leaving potential revenue on the table.
This aggregate rating is based on analysts' research of PTC Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
PTC Therapeutics (PTCT) Analyst Forecast & Price Prediction
Start investing in PTC Therapeutics (PTCT)
Order type
Buy in
Order amount
Est. shares
0 shares